Triplet Therapeutics
Jeff Cerio joined Triplet Therapeutics, Inc. in 2019 and serves as General Counsel and has more than 10 years of experience leading and advising life sciences companies on various legal matters relating to corporate governance, business development, financing, securities law, compliance and intellectual property. Before joining Triplet, he served as Senior Corporate Counsel, Securities at Moderna, Inc. where he helped lead the team in support of that company’s initial public offering. Previously Jeff served as a member of the legal team at Alkermes plc in roles of increasing responsibility, and prior to that was a corporate attorney in the life sciences practice at the law firm Ropes & Gray LLP. Jeff received his Pharm.D. from Northeastern University and his J.D. from the University of Connecticut School of Law.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.